---
title: Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia
date: '2024-04-24'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38657265/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20240425181109&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: Treatment with exa-cel, preceded by myeloablation, resulted
  in transfusion independence in 91% of patients with transfusion-dependent β-thalassemia.
  (Supported by Vertex Pharmaceuticals and CRISPR Therapeutics; CLIMB THAL-111 ClinicalTrials.gov
  number, ...'
disable_comments: true
---
CONCLUSIONS: Treatment with exa-cel, preceded by myeloablation, resulted in transfusion independence in 91% of patients with transfusion-dependent β-thalassemia. (Supported by Vertex Pharmaceuticals and CRISPR Therapeutics; CLIMB THAL-111 ClinicalTrials.gov number, ...